- Bruker Corporation (BRKR, Financial) unveils the timsMetabo™ Mass Spectrometer at the 73rd Conference on Mass Spectrometry.
- The novel instrument boasts exceptional 4D-Metabolomics sensitivity and specificity with the new TIMS 'MoRE' scan-mode.
- Bruker introduces QSee™ QC suite with cloud-based TwinScape™ for enhanced performance monitoring.
Bruker Corporation (BRKR), a prominent player in the field of scientific instruments, has launched the innovative timsMetabo™ mass spectrometer, a cutting-edge instrument designed to enhance 4D-Metabolomics and 4D-Lipidomics capabilities. Unveiled at the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), this new system offers unprecedented sensitivity, separation power, and annotation confidence for small molecule analyses, made possible by the novel TIMS 'MoRE' scan-mode.
The timsMetabo system generates a 'digital metabolome archive' for each sample, allowing for greatly increased confidence in automated annotation. It leverages 4D separations and reproducible molecular collision cross sections (CCS) for scaled 4D-Metabolomics and 4D-Lipidomics. The platform's exceptional resolution capabilities make it suitable for resolving isomers and conducting highly-selective MS1-based quantification challenges.
In addition to the hardware advancements, Bruker has introduced the QSee™ quality control suite, a sophisticated solution for automated evaluation of instrument performance. This suite, alongside the cloud-based TwinScape™ software, offers enhanced long-term monitoring. Collaborations with partners, such as Polymer Factory Sweden AB, have enriched the SpheriCal® platform, further enhancing performance assessment capabilities.
Industry experts have praised the timsMetabo's ability to facilitate the exploration of new metabolic signatures and the understanding of complex biological molecules such as bile acids. The combination of ion mobility advancements and precise CCS values has been highlighted as a significant step forward in clinical research and therapeutic discovery.
Dr. Matthew Lewis, Vice President of Metabolomics and Lipidomics at Bruker, emphasized the company's commitment to innovation, stating that the timsMetabo represents a transformative advancement in the application of 4D-Metabolomics and 4D-Lipidomics by delivering unique data analysis capabilities and enhanced quality monitoring.
